Delayed initiation or inadequate use of disease-modifying anti-rheumatic drugs is a significant challenge in managing rheumatic diseases. Early, hierarchical and aggressive therapy of these drugs is essential to prevent irreversible joint damage, organ complications and diminished quality of life. In addition, long-term use of corticosteroids does improve the signs and symptoms of the disease; however, it can also lead to potentially serious side effects like osteoporosis, diabetes and infections while delaying effective disease-modifying anti-rheumatic drugs’ use. On the other hand, inadequate monitoring of drug toxicities, such as hepatotoxicity or retinal damage, and failure to address immunosuppression-related infection risks can result in significant morbidity. Furthermore, polypharmacy and drug interactions, combined with inconsistent patient adherence, further hinder effective treatment. An effective strategy is to adopt a treat-to-target approach, prioritise corticosteroid-sparing therapies, monitor for drug toxicities and implement infection prevention protocols. Finally, in some instances, a proactive, multidisciplinary approach is vital for improving outcomes and minimising complications in the management of rheumatic diseases.